1-chloro-5-isoquinolinesulfonyl chloride hydrochloride | 105627-81-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 1-chloro-5-isoquinolinesulfonyl chloride hydrochloride
• 英文别名: 1-Chloroisoquinoline-5-sulfonyl chloride hydrochloride；1-chloroisoquinoline-5-sulfonyl chloride;hydrochloride
• CAS: 105627-81-4
• 化学式: C₉H₅Cl₂NO₂S*ClH
• 分子量: 298.577
• InChiKey: CSGOGYMPINXURE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.24
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-氨基哌啶 、 1-chloro-5-isoquinolinesulfonyl chloride hydrochloride 以 (2S)-N-methyl-1-phenylpropan-2-amine hydrate 、 二氯甲烷 为溶剂， 以84%的产率得到1-(1-chloro-5-isoquinolinesulfonyl)-3-aminopiperidine
  参考文献：
  名称：

  Isoquinoline derivatives

  摘要：

  公开号：

  EP0287696B1
• 作为产物：
  描述：

  1-氯-5-异喹啉磺酸 在 氯化亚砜 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-chloro-5-isoquinolinesulfonyl chloride hydrochloride
  参考文献：
  名称：

  Substituted isoquinolinesulfonyl compounds

  摘要：

  一种由化学式(I)表示的异喹啉磺酰化合物：其中R.sup.1：H、Cl、OH A：未取代或取代的乙烯或烷基R.sup.2、R.sup.3：H、烷基，共同形成未取代或取代的乙烯或三亚甲基R.sup.4：H、烷基、氨基甲酰基或其酸盐。例如，可以通过将1-R.sup.1取代-5-异喹啉磺酸转化为相应的磺酰氯，然后将氯化物与化学式的化合物反应来制备它们。它们可优势用作血管扩张剂、脑循环改善剂、降压药和预防治疗各种循环器官疾病的药物。

  公开号：

  US04678783A1

文献信息

• 5-Substituted isoquinoline derivatives
  申请人：Yamada Rintaro

  公开号：US20050020623A1

  公开（公告）日：2005-01-27

  A compound represented by the following formula (1) or a salt thereof: wherein R 1 represents hydrogen atom, a halogen atom and the like; R 2 represents hydrogen atom, a halogen atom, a C 1-6 alkyl group and the like; and R 3 represents —O—X—C(A 1 )(A 11 )—C(A 2 )(A 2l )—N(A 3l )(A 3 )(X represents propylene group etc., A 11 and A 21 represent hydrogen atom, or a C 1-6 alkyl group, A 31 represents a C 1-6 alkyl group substituted with hydroxyl group, or hydrogen atom, and A 1 , A 2 , and A 3 represent hydrogen atom, a C 1-6 alkyl group and the like) and the like, which has an inhibitory activity on the phosphorylation of myosin regulatory light chain, and is useful for treatment of diseases relating to contraction of various cells and the like.

  由以下公式（1）表示的化合物或其盐： 其中R1代表氢原子、卤素原子等；R2代表氢原子、卤素原子、C1-6烷基团等；R3代表—O—X—C(A1)(A11)—C(A2)(A21)—N(A31)(A3)（X代表丙烯基等，A11和A21代表氢原子或C1-6烷基团，A31代表被羟基取代的C1-6烷基团或氢原子，A1、A2和A3代表氢原子、C1-6烷基团等）等，该化合物对肌球蛋白调节轻链的磷酸化具有抑制作用，并且对涉及各种细胞收缩等的疾病的治疗有益。
• Isoquinoline-or quinoline-sulfonamide derivative and a pharmaceutical
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：US05340811A1

  公开（公告）日：1994-08-23

  Disclosed is a sulfonamide derivative represented by following formula (I) and a medicine for the treatment of asthma comprising the sulfonamide derivative as an active ingredient which exhibits bronchodilation effect. ##STR1## wherein X represents a quinoline residue represented by formula (II) or an isoquinoline residue represented by formula (III) ##STR2## where R.sup.1 is a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group, or ##STR3## where R.sup.2 is a hydrogen atom or a hydroxyl group, and wherein: when X is quinoline residue (II), n is zero or 1, in which, when n is zero, R.sup.4 is an unsubstituted or substituted diazacycloalkyl group, and when n is 1, R.sup.3 is a hydrogen atom or a lower alkyl group and R.sup.4 is an unsubstituted or substituted aralkylamino group or an unsubstituted or substituted diazacycloalkyl group; and when X is isoquinoline residue (III), n is 1, in which, R.sup.3 is a hydrogen atom or a lower alkyl group and R.sup.4 is a 3,4-methylenedioxyphenethylamino group, a 3,4-methylenedioxybenzylamino group or an unsubstituted or substituted diazacycloalkyl group, with the proviso that when R.sup.4 is an unsubstituted or substituted diazacycloalkyl group, the diazacycloalkyl group is bonded at a nitrogen atom thereof.

  本发明公开了一种磺胺衍生物，其表示为以下式（I），以及包含所述磺胺衍生物作为活性成分的治疗哮喘的药物，该药物具有支气管扩张作用。其中，X代表由式（II）表示的喹啉残基或由式（III）表示的异喹啉残基。其中，R.sup.1是氢原子、卤素原子、低碳基团或低烷氧基团，或者R.sup.2是氢原子或羟基，且当X为喹啉残基（II）时，n为零或1，其中当n为零时，R.sup.4是未取代或取代的二氮杂环烷基团，当n为1时，R.sup.3是氢原子或低碳基团，R.sup.4是未取代或取代的芳基氨基团或未取代或取代的二氮杂环烷基团；当X为异喹啉残基（III）时，n为1，其中，R.sup.3是氢原子或低碳基团，R.sup.4是3,4-亚甲二氧基苯乙胺基团、3,4-亚甲二氧基苄胺基团或未取代或取代的二氮杂环烷基团，但当R.sup.4是未取代或取代的二氮杂环烷基团时，该二氮杂环烷基团与其氮原子结合。
• 5-substituted isoquinoline derivatives
  申请人：Asahi Kasei Pharma Corporation

  公开号：US07094789B2

  公开（公告）日：2006-08-22

  A compound represented by the following formula (1) or a salt thereof: wherein R1 represents hydrogen atom, a halogen atom and the like; R2 represents hydrogen atom, a halogen atom, a C1-6 alkyl group and the like; and R3 represents —O—X—C(A1)(A11)-C(A2)(A21)-N(A31)(A3) (X represents propylene group etc., A11 and A21 represent hydrogen atom, or a C1-6 alkyl group, A31 represents a C1-6 alkyl group substituted with hydroxyl group, or hydrogen atom, and A1, A2, and A3 represent hydrogen atom, a C1-6 alkyl group and the like) and the like, which has an inhibitory activity on the phosphorylation of myosin regulatory light chain, and is useful for treatment of diseases relating to contraction of various cells and the like.

  下列化合物的分子式（1）或其盐：其中，R1代表氢原子、卤原子等；R2代表氢原子、卤原子、C1-6烷基等；R3代表-O-X-C（A1）（A11）-C（A2）（A21）-N（A31）（A3）（X代表丙烯基等，A11和A21代表氢原子或C1-6烷基，A31代表一个带有羟基取代的C1-6烷基或氢原子，A1、A2和A3代表氢原子、C1-6烷基等），该化合物具有对肌球蛋白调节轻链磷酸化的抑制活性，可用于治疗与各种细胞收缩相关的疾病等。
• 5-SUBSTITUTED ISOQUINOLINE DERIVATIVE
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP1541559A1

  公开（公告）日：2005-06-15

  A compound represented by the following formula (1) or a salt thereof: wherein R1 represents hydrogen atom, a halogen atom and the like; R2 represents hydrogen atom, a halogen atom, a C1-6 alkyl group and the like; and R3 represents -O-X-C(A1)(A11)-C(A2)(A21)-N(A31)(A3) (X represents propylene group etc., A11 and A21 represent hydrogen atom, or a C1-6 alkyl group, A31 represents a C1-6 alkyl group substituted with hydroxyl group, or hydrogen atom, and A1, A2, and A3 represent hydrogen atom, a C1-6 alkyl group and the like) and the like, which has an inhibitory activity on the phosphorylation of myosin regulatory light chain, and is useful for treatment of diseases relating to contraction of various cells and the like.

  下式（1）所代表的化合物或其盐： 其中 R1 代表氢原子、卤素原子等；R2 代表氢原子、卤素原子、C1-6 烷基等；R3 代表-O-X-C(A1)(A11)-C(A2)(A21)-N(A31)(A3) （X 代表丙烯基等）、A11和A21代表氢原子或C1-6烷基，A31代表被羟基或氢原子取代的C1-6烷基，A1、A2和A3代表氢原子、C1-6烷基等）等，对肌球蛋白调节轻链的磷酸化具有抑制活性，可用于治疗与各种细胞收缩有关的疾病等。
• SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：EP0471841B1

  公开（公告）日：1995-11-02